New CAR T-Cell therapy targets Hard-to-Treat myeloma
Disease control
Not yet recruiting
This early-stage trial tests the safety of a new CAR T-cell therapy, UF-KURE-BCMA, in 12 adults with multiple myeloma that has returned or not responded to other treatments. The therapy uses specially engineered immune cells to target and attack cancer cells. The main goal is to …
Phase: PHASE1 • Sponsor: Kure Cells, INC • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC